Clovibactin – a game-changing novel antibiotic with no resistance

Researchers reported the discovery of a new antibiotic, clovibactin.

Risk Adjusted Net Present Value: What is the current valuation of PDS Biotechnology’s PDS-0101

The revenue for PDS-0101 is expected to reach an annual total of $170 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue

September 19, 2023

Gastric bypass and sleeve tie in short-term complications

The two most common obesity surgeries – gastric bypass and gastric sleeve – have few short-term complications and are equivalent in that sense.

January 30, 2024

OcuTerra’s diabetic retinopathy drug fails PhII; Better Therapeutics to shut down

Plus, news about Immuneering, Aditum Bio, Unicycive and X-Therma: OcuTerra Therapeutics’ diabetic retinopathy drug fails PhII: The company’s RGD integrin inhibitor did not meet the

March 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.